Choi David, Zuckerman Autumn D, Gerzenshtein Svetlana, Katsivalis Katherine V, Nichols Patrick J, Saknini Marci C, Schneider Megan P, Taylor Paige, Dusetzina Stacie B
Department of Pharmacy, University of Chicago Medicine, IL (Choi, Gerzenshtein, Katsivalis, Taylor).
Department of Pharmaceutical Services, Vanderbilt University Medical Center, Nashville, TN (Zuckerman, Nichols, Saknini, Schneider).
J Manag Care Spec Pharm. 2024 Aug;30(8):883-896. doi: 10.18553/jmcp.2024.30.8.883.
Insurer or self-insured employer's plans are increasingly using copay accumulator, copay maximizer, and alternative funding programs (AFPs) to reduce plan spending on high-priced prescriptions. These programs differ in their structure and impact on patient affordability but typically decrease the insurer or self-insured employer's financial responsibility for high-priced drugs and increase the complexity of specialty medication access for patients. The aim of this primer is to describe the structure of copay accumulator, copay maximizer, and AFPs to improve understanding of these cost-shifting strategies and help clinicians and patients navigate medication access and affordability issues to minimize treatment delays or non-initiation.
保险公司或自保雇主计划越来越多地使用共付额累积器、共付额最大化器和替代资金计划(AFP)来减少高价处方药的计划支出。这些计划在其结构以及对患者可承受性的影响方面存在差异,但通常会降低保险公司或自保雇主对高价药品的财务责任,并增加患者获取专科药物的复杂性。本入门指南的目的是描述共付额累积器、共付额最大化器和AFP的结构,以增进对这些成本转移策略的理解,并帮助临床医生和患者应对药物获取和可承受性问题,以尽量减少治疗延迟或不开始治疗的情况。